Neogen Corporation — FY2013 Form 10-K
Reporting period: Fiscal year ended May 31, 2013, compared primarily with FY2012. The request labels the period “2012 Q4,” but this filing is an annual report for FY2013; it includes quarterly results for the quarter ended May 31, 2013.
Business context and performance
Neogen develops, manufactures, and sells food-safety testing products and animal-safety products and services, including veterinary products and genomics testing. FY2013 revenue was $207.5 million: Food Safety contributed $106.2 million and Animal Safety $101.4 million.
| Metric | FY2013 | FY2012 |
|---|---|---|
| Total revenue | $207.5 million | $184.0 million |
| Gross margin | $109.5 million; 52.8% | $92.4 million; 50.2% |
| Operating income | $40.7 million; 19.6% of revenue | $33.7 million; 18.3% of revenue |
| Net income attributable to Neogen | $27.2 million; diluted EPS $1.12 | $22.5 million; diluted EPS $0.94 |
| Cash from operating activities | $26.6 million | $22.3 million |
| Cash and marketable securities at year-end | $85.4 million | $68.6 million |
| Working capital at year-end | $150.7 million | $124.0 million |
| Long-term debt | None | None |
Changes versus FY2012
- Revenue rose 13%; Food Safety revenue increased 17% and Animal Safety revenue 9%. Service revenue increased 22% to $23.4 million.
- Gross margin improved to 52.8% from 50.2%, mainly from Animal Safety product mix and a higher Food Safety share of sales. Operating expenses rose 17%, faster than revenue, reflecting investment in sales, marketing, staffing, and infrastructure.
- Operating income and attributable net income each increased 21%. Operating margin rose from 18.3% to 19.6%.
- Operating cash flow increased 19%. Cash and marketable securities grew by $16.7 million; the company spent $13.3 million on acquisitions and $8.9 million on property and equipment.
Outlook, risks, and notable items
- Management does not provide forecasts of future financial performance. It expects R&D spending to remain approximately 3%–5% of revenue and expects products under development to become marketable in FY2014–FY2016.
- Management cited growth priorities including new products, increased use of existing products, international expansion, margin management, and acquisitions. Acquisitions contributed $5.8 million of Animal Safety revenue in FY2013.
- Notable demand drivers included toxin-testing demand following weather-related crop outbreaks and increased European meat-speciation testing following food-mislabelling discoveries. Management suggested elevated speciation testing could continue, but this is not formal guidance.
- Key risks include acquisition integration and execution, product-development uncertainty, competition, agricultural-market cyclicality and weather, international regulation and currency exposure, intellectual-property disputes, supply disruption, and reliance on key personnel. International sales were 40.1% of revenue.
- The company disclosed a $12 million undrawn revolving credit facility, expiring September 2014. Contractual obligations totaled $35.2 million, including $33.4 million of unconditional purchase obligations. Management noted future acquisitions or product commercialization could require additional financing.
- Environmental remediation at the Randolph, Wisconsin facility carries an estimated $916,000 liability, with annual costs historically ranging from $50,000 to $105,000. Other legal proceedings were described as not expected to have a material effect.
- Acquisitions included Macleod Pharmaceuticals and Scidera Genomics during FY2013. After year-end, Neogen acquired SyrVet for $10.0 million cash plus potential secondary consideration of up to $1.5 million. President and COO Lon Bohannon planned to retire August 31, 2013; Stephen Snyder was expected to succeed him.
- Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting. Management also concluded disclosure controls were effective.
Investor verification priorities
- Reconcile the period requested with the filing: annual FY2013 results, not a standalone FY2012 fourth-quarter filing.
- Assess the durability of margin gains and whether expense growth and acquisition contributions support continued earnings growth.
- Review acquisition integration, purchase-price allocations, contingent payments, and the post-year-end SyrVet transaction.
- Evaluate cash conversion and near-term commitments, especially unconditional purchase obligations and royalty minimums.
- Monitor performance in weaker product areas, including racing kits, food-residue testing, vaccines, and cleaners/disinfectants, alongside weather-driven testing demand.
- Verify leadership-transition execution and the company’s exposure to foreign currencies, regulation, and agricultural-market conditions.